U.S. Interactive Media and Services Stock News

NYSE:KVYO
NYSE:KVYOSoftware

Klaviyo Claude Integration Shifts AI To Execution As Shares Screen Undervalued

Klaviyo (NYSE:KVYO) has launched a deeper integration with Anthropic's Claude through a new Model Context Protocol connector. The update allows marketers to use natural language inside Claude to pull Klaviyo first party data, generate campaigns, and automate multi step workflows. This moves Klaviyo's AI tools from insight generation into direct execution across reporting and campaign creation. Klaviyo is rolling out this Claude integration at a time when the stock is trading at $14.24 and...
NYSE:AON
NYSE:AONInsurance

Has Aon (AON) Share Weakness Opened A Valuation Opportunity For Investors

Wondering whether Aon’s current share price still reflects good value, or if most of the opportunity has already been priced in? This article looks at the stock through a clear valuation lens so you can frame your own view. Aon’s share price closed at US$310.90, with returns of 0.9% over the past week, a decline of 4.5% over the past month, a decline of 9.7% year to date and a decline of 10.9% over the past year. These figures may change how investors think about its risk and return trade...
NasdaqGS:HUMA
NasdaqGS:HUMABiotechs

Does Humacyte’s (HUMA) Nasdaq Notice Quietly Reframe Its Financing Flexibility And Clinical Adoption Story?

In the first quarter of 2026, Humacyte, Inc. reported revenue of US$495,000, sales of US$2,000, and a net loss of US$17.62 million, alongside a Nasdaq notice that its share price had stayed below the US$1.00 minimum listing requirement. The sharp swing from a US$39.14 million net profit a year earlier to a loss, combined with the compliance warning, raises questions about Humacyte’s operating trajectory and financing flexibility even as it appoints a new Chief Surgical Officer to support...
NasdaqGM:LGND
NasdaqGM:LGNDPharmaceuticals

A Look At Ligand Pharmaceuticals (LGND) Valuation After XOMA Deal And Viking TR Beta Licensing Dispute

Ligand Pharmaceuticals (LGND) is back in focus after its latest quarterly update, which combined higher royalty revenues and adjusted EPS with the planned XOMA acquisition and a contested termination of the Viking TR Beta licensing program. See our latest analysis for Ligand Pharmaceuticals. The stock has eased in the very short term, with a 7 day share price return of down 4.9%. However, the 90 day share price return of 21.8% and the 1 year total shareholder return of 110.5% point to strong...
NYSE:VMI
NYSE:VMIConstruction

How Investors May Respond To Valmont Industries (VMI) Profitability Gains And Positive Analyst Sentiment

In recent months, Valmont Industries has reported strong earnings per share growth and a wider free cash flow margin, while analysts and brokers have maintained favorable rankings and recommendations based on its fundamentals. This combination of rising profitability metrics and broadly positive analyst sentiment has reinforced the view that Valmont’s operational improvements are materially strengthening its underlying business quality. With this backdrop of improving profitability and...